Opinion: Race for a COVID-19 vaccine could be risky

The race for a COVID-19 vaccine has led to concerns from health professionals as well as Americans wondering whether or not a safe and reliable vaccine will be ready in the coming months.
The risk of rushing a vaccine so quickly could lead to a devastating amount of underlying problems that go beyond the virus itself. Not giving enough time for all the flaws of the vaccine to be tested while producing millions of doses could lead to side effects and other issues, inevitably discrediting the vaccine.
Recently, President Donald Trump announced the possibility of a vaccine being available as early as October. This has a lot of people skeptical about whether or not the vaccine will be safe for the public, or there will be enough doses in time for that deadline.
A main issue with rushing a vaccine is making it available to anyone, which will help to slow the spread of the virus once people get the vaccine. By getting it out as soon as possible, it limits the availability of the vaccine to the public, since there won’t be enough doses to be used nationally.
Russia is the first country to publicly release a vaccine for domestic use, which is currently being tested in countries like Brazil, and others around the world. Russia’s health ministry claims that the first batch of the vaccine, “passed all necessary quality tests and shipments to regions around Russia will begin in the near future.”
However, no data has been posted about the effectiveness of the vaccine since it was approved, and no late-phase testing was completed. This has led scientists internationally to question the research behind the COVID-19 vaccine, and if rushing the vaccine out will have any everlasting effects on people wanting to get one. Since the vaccine has been created extremely fast, it’s important to analyze the research and the underlying data behind the creation of it to see if it will be safe for the public to get.
While having a vaccine will be comforting for some people, the lack of availability will affect the widespread usage of the vaccine. Most likely there will be not enough doses once a vaccine is approved and released, which will extend the amount of time before the majority of the population is able to get vaccinated. It would be better for the creation of a vaccine to be researched more so there will be less flaws when it is released, additionally giving time to companies who are producing dosages worldwide.